Can tuberculosis (TB) cause warm autoimmune hemolytic anemia (AIHA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can Tuberculosis Cause Warm AIHA?

Yes, tuberculosis can cause warm autoimmune hemolytic anemia (AIHA), though it is a rare complication of TB infection. This association is well-documented in case reports and systematic reviews, with TB-induced AIHA representing an uncommon but recognized hematological manifestation of tuberculosis 1, 2.

Evidence for TB-Induced Warm AIHA

The connection between tuberculosis and warm AIHA is established through multiple case reports and systematic analyses:

  • A systematic review of 21 published cases found that TB-induced AIHA presents with positive direct Coombs test in all patients, with mean hemoglobin of 5.77 g/dl 2
  • Pulmonary tuberculosis was the most common form (43%) associated with AIHA, though disseminated TB also causes this complication 2
  • Recent case reports confirm TB can trigger refractory AIHA requiring combination therapy 1, 3

Clinical Presentation

When TB causes warm AIHA, patients typically present with:

  • Fever and pallor in more than half of cases 2
  • Severe anemia (mean Hb ~5.8 g/dl) with positive direct antiglobulin test 2
  • Constitutional symptoms that may overlap with TB itself (weight loss, fever) 4

Pathophysiologic Mechanism

TB induces autoimmune hemolysis through immune dysregulation, with IgG autoantibodies produced against red blood cells leading to extravascular hemolysis via antibody-dependent cellular cytotoxicity 5. The exact mechanism involves breakdown of immune tolerance triggered by chronic infection 6.

Treatment Approach

The management requires a three-pronged approach: anti-tuberculosis medications, corticosteroids, and blood transfusions as needed 2:

  • All patients require standard anti-TB therapy as the primary treatment 2
  • Corticosteroids are indicated, particularly in disseminated TB-induced AIHA (67% of cases required steroids versus only 13% in localized TB) 2
  • Prednisone is FDA-approved for acquired (autoimmune) hemolytic anemia 7
  • Rituximab may be added for refractory cases not responding to steroids and anti-TB treatment 1, 8
  • Blood transfusions are used for severe symptomatic anemia 2

Important Clinical Considerations

Physicians should maintain high suspicion for TB as a cause of AIHA, especially in TB-endemic regions 2. The diagnosis requires:

  • Positive direct antiglobulin test (DAT) to confirm AIHA 8
  • Identification of active TB through appropriate microbiological and radiological studies 2
  • Exclusion of other secondary causes of warm AIHA, particularly lymphoproliferative disorders like CLL 5

The hematologic complications typically improve with successful TB treatment, confirming the causal relationship 3. This distinguishes TB-induced AIHA from primary AIHA or other secondary causes that may not resolve with infection treatment alone.

References

Research

Case Report: Tuberculosis-Induced Autoimmune Hemolytic Anemia.

The American journal of tropical medicine and hygiene, 2023

Research

Tuberculosis induced autoimmune haemolytic anaemia: a systematic review to find out common clinical presentations, investigation findings and the treatment options.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2018

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Causes of Warm Autoimmune Hemolytic Anemia (AIHA)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Autoimmune hemolytic anemia: causes and consequences.

Expert review of clinical immunology, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.